A decade of progress in kidney transplantation

Transplantation

Volumn 77, Issue 9, 2004, Pages

  Vincenti, Flavio ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG SAFETY; GINGIVA HYPERPLASIA; GRAFT REJECTION; HIRSUTISM; HUMAN; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; HYPERTENSION; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SURGICAL TECHNIQUE; SURVIVAL;

EID: 2442642635     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000126928.15055.dc     Document Type: Review

References (52)

1. Hariharan S, Johnson CP, Bresnahan BA, et al. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med 2000; 342: 605.
2. Matas AJ, Gilingham KJ, Payne WD, et al. The impact of an acute rejection episode on long-term renal allograft survival (t1/2). Transplantation 1994; 57: 857.
3. Ojo AO, Port FK, Held PJ, et al. Inferior outcomes of two-haplotype matched renal transplants in blacks: role of early rejection. Kidney Int 1995; 48: 1592.
4. Pirsch JD, Miller J, Deierhoi MH, et al., for the FK506 Kidney Transplant Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997; 63: 977.
5. Neylan JF, for the FK506 Kidney Transplant Study Group. Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 1998; 65: 515.
6. Johnson C, Ahsan N, Gonwa T, et al. Randomized trial of tacrolimus (Prograf) in combination with azathioprine or mycophenolate mofetil versus cyclosporine (Neoral) with mycophenolate mofetil after cadaveric kidney transplantation. Transplantation 2000; 9: 834.
7. Gonwa T, Mendez R, Yang HC, et al., for the Prograf Study Group. Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 6 months. Transplantation 2003; 75: 1213-1220.
8. Miller J, Burke GW, Ciancio G, et al. Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection [abstract]. From the Proceedings of the 2003 American Transplantation Congress, May 30-June 4, 2003, Washington, DC. Abstract 1222.
9. Jensik SC, for the FK 506 Kidney Transplant Study Group. Tacrolimus (FK 506) in kidney transplantation: three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 1998; 30: 1216.
10. Ahsan N, Johnson C, Gonwa T, et al. Randomized trial of tacrolimus plus mycophenolate mofetil or azathioprine versus cyclosporine oral solution (modified) plus mycophenolate mofetil after cadaveric kidney transplantation: results at 2 years. Transplantation 2001; 72: 245.
11. Gonwa T, Johnson C, Ahsan N, et al. Randomized trial of tacrolimus + mycophenolate mofetil or azathioprine versus cyclosporine + mycophenolate mofetil after cadaveric kidney transplantation: results at three years. Transplantation 2003; 75: 2045.
12. Margreiter R, for the European Tacrolimus vs Ciclosporin Microemulsion Renal Transplant Study Group. Efficacy and safety of tacrolimus compared with ciclosporin microemulsion in renal transplantation: a randomised multicentre study. Lancet 2002; 359: 741.
13. Vincenti F, Jensik SC, Filo RS, et al. A long-term comparison of tacrolimus (FK506) and cyclosporine in kidney transplantation: evidence for improved allograft survival at five years. Transplantation 2002; 73: 775.
14. Foster CE, Philosophe B, Schweitzer EJ, et al. A decade of experience with renal transplantation in African-Americans. Ann Surg 2002; 236: 794.
15. Bresnahan BA, Cherikh WS, Cheng Y, et al. Short-term benefit of tacrolimus vs cyclosporine therapy after renal transplantation: an analysis of UNOS/OPTN database [abstract]. From the Proceedings of the 2003 American Transplantation Congress, May 30-June 4, 2003, Washington, DC. Abstract 1213.
16. Gourishankar S, Hunsicker LG, Jhangri GS, et al. The stability of the glomerular filtration rate after renal transplantation is improving. J Am Soc Nephrol 2003; 14: 2387.
17. Kaplan B, Schold JD, Meier-Kriesche H-U. Long-term graft survival with Neoral and tacrolimus: a paired kidney analysis. J Am Soc Nephrol 2003; 14: 2980.
18. Klein IH, Abrahams A, van Ede T, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732.
19. Waid TH. Prografas secondary intervention vs continuation of cyclosporine in patients at risk for chronic renal allograft failure (CRAF) results in improved renal function, decreased CV risk, and no increased risk for diabetes [abstract]. From the Proceedings of the 2003 American Transplantation Congress, May 30-June 4, 2003. Washington, DC. Abstract 1111.
20. Neu AM, Ho PL, Fine RN, et al. Tacrolimus vs cyclosporine A as primary immunosuppression in pediatric renal transplantation: a NAPRTCS study. Pediatr Transplant 2003; 7: 217.
21. Fellström B. Risk factors for and management of post-transplantation cardiovascular disease. Biodrugs 2001; 15: 261.
22. Wissing KM, Abramowicz D, Broeders N, et al. Hypercholesterolemia is associated with increased kidney graft loss caused by chronic rejection in male patients with previous acute rejection. Transplantation 2000; 70: 464.
23. Satterthwaite R, Aswad S, Sunga V, et al. Incidence of new-onset hypercholesterolemia in renal transplant patients treated with FK506 or cyclosporine. Transplantation 1998; 65: 446.
24. Ligtenberg G, Hené RJ, Blankestijn PJ, et al. Cardiovascular risk factors in renal transplant patients: cyclosporine A versus tacrolimus. J Am Soc Nephrol 2001; 12: 368.
25. McCune TR, Thacker LR II, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful renal transplantation. Transplantation 1998; 65: 87.
26. Donahoo WT, Kosmiski LA, Eckel RH. Drugs causing dyslipoproteinemia. Endocrin Metab Clin North Am 1998; 27: 677.
27. Taler SJ, Textor SC, Canzanello VJ, et al. Role of steroid dose in hypertension early after liver transplantation with tacrolimus (FK506) and cyclosporine. Transplantation 1996; 62: 1588.
28. Schulak JA, Hricik DE. Steroid withdrawal after renal transplantation. Clin Transplant 1994; 8: 211.
29. Peschke B, Scheuermann EH, Geiger H, et al. Hypertension is associated with hyperlipidemia, coronary heart disease and chronic graft failure in kidney transplant recipients. Clin Nephrol 1999; 51(5): 290.
30. Demme R. Hypertension in the kidney transplant patient. Graft 2001; 4: 248.
31. Pirsch J, Bekersky I, Vincenti F, et al. Coadministration of tacrolimus and mycophenolate mofetil in stable kidney transplant patients: pharmacokinetics and tolerability. J Clin Pharmacol 2000; 40: 527.
32. Cosio FG, Pesavento TE, Osei K, et al. Post-transplant diabetes mellitus: increasing incidence in renal allograft recipients transplanted in recent years. Kidney Int 2001; 59: 732.
33. Van Duijnhoven EM, Boots JM, Christiaans MH, et al. Metabolic aspects of tacrolimus in renal transplantation. Minerva Urol Nephrol 2003; 55: 1.
34. Kreis H, Cisterne JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
35. Rostaing L, Catarovich D, Mourad G, et al., for the CARMEN Study Group. Steroid-free immunosuppression with a combination of daclizumab, tacrolimus and MMF is efficacious and safe: results of a large multicenter trial in renal transplantation [abstract]. From the Proceedings of the 2003 American Transplantation Congress, May 30-June 4, 2003, Washington, DC. Abstract 627.
36. First MR, Gerber DA, Hariharan S, et al. Posttransplant diabetes mellitus in kidney allograft recipients: incidence, risk factors, and management. Transplantation 2002; 73: 379.
37. Romagnoli J, Citterio F, Scata MC, et al. Different patterns of posttransplant diabetes mellitus under different immunosuppressive protocols [abstract]. Poster abstract presented at the XIX International Congress of The Transplantation Society, August 29-30, 2002, Miami, FL. Abstract 2104.
38. Schwimmer J, Zand MS. Management of diabetes mellitus after solid organ transplantation. Graft 2001; 4: 256.
39. Hricik DE, Bartucci MR, Moir EJ, et al. Effects of steroid withdrawal on posttransplant diabetes mellitus in cyclosporine-treated renal transplant recipients. Transplantation 1991; 51: 374.
40. Boots JM, Van Duijnhoven EM, Christiaans MH, et al. Glucose metabolism in renal transplant recipients on tacrolimus: the effect of steroid withdrawal and tacrolimus trough level reduction. J Am Soc Nephrol 2002; 13: 221.
41. Woodle ES, for the Fujisawa Steroid Withdrawal Group. A prospective, randomized, double blind, multicenter trial of early (7 day) corticosteroid cessation vs long term low dose corticosteroid therapy under tacrolimus and mycophenolate mofetil therapy with antibody induction [abstract]. From the Proceedings of the 2003 American Transplantation Congress, May 30-June 4, 2003, Washington, DC. Abstract 183.
42. Kandaswamy R, Humar A, Khwaja K, et al. A prospective randomized study of cyclosporine (CSA)/Cellcept (MMF) vs tacrolimus (TAC)/sirolimus (SIR) with rapid discontinuation of prednisone(P) [abstract]. From the Proceedings of the 2003 American Transplantation Congress, May 30-June 4, 2003, Washington, DC. Abstract 182.
43. Mayer D, Boillot O, Boudjema K, and the Master study group. Steroid-free immunosuppression with tacrolimus after daclizumab induction: a multicentre, comparative, randomised study [abstact]. From the Proceedings of the 2003 11th ESOT and 13th ETCO Congress, September 20-24, 2003, Venice, Italy. Abstract FG01-26.
44. Sarwal M, Yorgin PD, Alexander S, et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001; 72: 13.
45. DeGeest S, Borgermans L, Gemoets, et al. Incidence, determinants, and consequences of subclinical noncompliance with immunosuppressive therapy in renal transplant recipients. Transplantation 1995; 59: 340.
46. Sketris I, Waite N, Grobler K, et al. Factors affecting compliance with cyclosporine in adult renal transplant patients. Transplant Proc 1994; 26: 2538.
47. Danovitch GM. The epidemic of cardiovascular disease in chronic renal disease: a challenge to the transplant physician. Graft 1999; 2(suppl): S108.
48. Thorp M, DeMattos A, Bennett W, et al. The effect of conversion from cyclosporine to tacrolimus on gingival hyperplasia, hirsutism, and cholesterol. Transplantation 2000; 69: 1218.
49. Didlake RH, Dreyfus K, Kerman RH, et al. Patient noncompliance: a major cause of late graft failure in cyclosporine-treated renal transplants. Transplant Proc 1988; 20(suppl 3): 63.
50. Gaston RS. Maintenance immunosuppression in the renal transplant recipient: an overview. Am J Kidney Dis 2001; 38(suppl 6): S25.
51. Ahsan H, Hricik D, Matas A, et al., for the Steroid Withdrawal Study Group. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil: a prospective randomized study. Transplantation 1999; 68: 1865.
52. Buell JF, Kulkarni S, Grewal HP, et al. Early corticosteroid cessation at one week following kidney transplant under tacrolimus and mycophenolate mofetil (MMF) immunosuppression, three-year follow-up [abstract]. Transplantation 2000; 69: S134. Abstract A88.